Tesaro Inc. (TSRO) PT Raised to $128.00 at RBC Capital Markets
Tesaro Inc. (NASDAQ:TSRO) had its target price increased by equities research analysts at RBC Capital Markets from $122.00 to $128.00 in a report issued on Monday. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. RBC Capital Markets’ target price would indicate a potential upside of 10.99% from the stock’s previous close.
Several other analysts also recently weighed in on the company. Wedbush boosted their target price on Tesaro from $107.00 to $139.00 and gave the company an “outperform” rating in a report on Monday. Royal Bank Of Canada boosted their target price on Tesaro from $122.00 to $128.00 and gave the company an “outperform” rating in a report on Monday. Bank of America Corp. raised Tesaro from a “neutral” rating to a “buy” rating and set a $123.00 target price for the company in a report on Monday. FBR & Co boosted their target price on Tesaro from $102.00 to $115.00 and gave the company an “outperform” rating in a report on Monday. Finally, SunTrust Banks Inc. reissued a “buy” rating and issued a $91.60 target price on shares of Tesaro in a report on Wednesday, September 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. Tesaro currently has an average rating of “Buy” and a consensus target price of $109.76.
Tesaro (NASDAQ:TSRO) opened at 115.33 on Monday. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The stock’s market cap is $5.92 billion. The firm’s 50-day moving average price is $97.53 and its 200-day moving average price is $70.11.
Tesaro (NASDAQ:TSRO) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.43. The company earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative return on equity of 205.63% and a negative net margin of 783.97%. During the same period in the previous year, the business earned ($1.51) EPS. On average, analysts predict that Tesaro will post ($7.36) earnings per share for the current year.
In other Tesaro news, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $88.54, for a total transaction of $619,780.00. Following the transaction, the vice president now owns 3,500 shares in the company, valued at approximately $309,890. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jeffrey H. Hanke sold 29,166 shares of the business’s stock in a transaction that occurred on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total value of $2,509,442.64. Following the transaction, the vice president now owns 29,166 shares in the company, valued at approximately $2,509,442.64. The disclosure for this sale can be found here. 40.50% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. acquired a new position in Tesaro during the second quarter valued at about $228,000. Amalgamated Bank acquired a new position in Tesaro during the second quarter valued at about $260,000. Quantitative Systematic Strategies LLC acquired a new position in Tesaro during the second quarter valued at about $240,000. Bluestein R H & Co. acquired a new position in Tesaro during the second quarter valued at about $252,000. Finally, Neuberger Berman Group LLC acquired a new position in Tesaro during the second quarter valued at about $256,000. Institutional investors own 88.81% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.